

MYHEALTHTEST WINS \$1m GRANT

ITL Ltd (“ITL”), the diversified healthcare company, is pleased to announce that MyHealthTest Pty Ltd (“MHT”), a company in which ITL has a strategic investment (announced 29 April 2015), has been awarded an Accelerating Commercialisation grant of up to \$1 million from the Commonwealth Department of Industry and Science.

The grant is for the commercialisation of dry blood spot pathology testing and the funds represent 40% of MHT’s approved budget for this project.

MHT is one of the first entrants into the direct to consumer pathology testing market and the grant will drive and underpin MHT’s growth as it seeks to provide an end to end convenient and cost saving experience for the consumer. MHT’s customers will order a home test kit online, receive it by post or collect it from a local pharmacy or GP, return the sample to MHT and they and their doctor receive the test results via a secure online portal.

MHT will serve chronic health conditions that require regular blood testing such as diabetes and cardiovascular disease. The Company will shortly launch a test used to diagnose and manage diabetes (the “HbA1c” test). Australia has 1.1 million diagnosed diabetics, an estimated 600,000 with undiagnosed diabetes and over 2 million with pre-diabetes (ref. Diabetes Australia).

The grant will also enable MHT to accelerate the launch of its convenient tests for thyroid and prostate conditions, and will help the Company establish advanced laboratory test processing facilities.

Bill Mobbs, ITL’s Executive Chairman commented “I would first of all like to thank the Commonwealth Department of Industry and Science .

This grant will allow MHT to achieve its goals over a considerably reduced time frame. MHT is already poised to launch its first test in the diabetes sector which we are now even more confident will provide the springboard for its expansion into testing for other chronic diseases in 2016.”

ITL (ASX: ITD, www.itl-limited.com) is a diversified healthcare company, specialising in innovative medical devices, procedure packs and medical equipment for global healthcare markets. ITL manufactures in Australia and Malaysia, and has sales offices in Australia, North America and Asia.

ITL Limited ABN 16 088 212 088

**Unit 1, 63 Wells Road
Chelsea Heights, Victoria, 3196**

ITL is a diversified healthcare company, specialising in innovative medical devices and procedure packs for global healthcare markets. ITL manufactures in Australia and Malaysia, and has sales offices in Australia, North America, and Asia.

ITL’s patented medical devices have a presence in over 35 countries and protect healthcare workers in millions of procedures annually. ITL supplies its range of customised medical procedure packs to over 200 hospitals across Australia.

Australian Securities Exchange

Code: ITD

Ordinary Shares

84,810,264

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Company Secretary
David Holden	Chief Financial Officer

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	info@itl-limited.com

www.itl-limited.com

Media

Ben Knowles	Walbrook IR
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.com.au